No Data
Beijing Wantai Biological Pharmacy Enterprise (603392.SH): Ye Xiangzhong intends to reduce his shareholding by no more than 0.1 million shares.
Gelonghui, February 11丨Beijing Wantai Biological Pharmacy Enterprise (603392.SH) announced that Mr. Ye Xiangzhong will reduce his shareholding in the company by no more than 100,000 shares (which does not exceed 0.0079% of the company's total shares and does not exceed 25% of his personal holdings) within three months after the 15th trading day from the date of this announcement through centralized bidding trading.
Wantai Biotech: Announcement on pre-reduction of Wantai Biotech\'s 2024 annual results
Wantai Biotech 2024 Annual Results Pre-Reduction Announcement
The growth of the diagnosis Sector does not hide the performance decline of Beijing Wantai Biological Pharmacy Enterprise; the Net income in 2024 may hit a new low since its listing. | Interpretations
① Beijing Wantai Biological Pharmacy Enterprise issued a performance reduction announcement, expecting that the net income attributable to the parent company in 2024 will decrease by more than 90% year-on-year; ② The main reason is the significant decline in income and profits from the vaccine Sector, leading to a net loss; ③ In Q4, the company incurred losses again, but the loss amount narrowed compared to the same period in 2023.
Express News | Wantai Biological Pharmacy Sees 2024 Net Profit Down 90.4-93.1% Y/Y
Beijing Wantai Biological Pharmacy Enterprise (603392.SH): It is expected that the net income in 2024 will decrease by 90.38%-93.11% year-on-year.
Gelonghui, January 15 - Beijing Wantai Biological Pharmacy Enterprise (603392.SH) announced that, according to preliminary estimates from the finance department, the expected net income attributable to the owners of the parent company for the fiscal year 2024 will be between 86 million yuan and 120 million yuan, compared to 1,247.68 million yuan in the same period last year, resulting in a decrease of 1,161.68 million yuan to 1,127.68 million yuan, representing a year-on-year decrease of 93.11% to 90.38%. The expected net income attributable to the owners of the parent company, excluding non-recurring gains and losses, for the fiscal year 2024 is estimated to be between -220 million yuan and -155 million yuan, compared to 107 million yuan in the same period last year.
102884128 : getting disappointed with this counter. every day drop.